Literature DB >> 8234174

Effect of apparent elimination half-life on nitroglycerin-induced hemodynamic rebound in experimental heart failure.

J A Bauer1, H L Fung.   

Abstract

Hemodynamic rebound after abrupt withdrawal may be an important consideration associated with nitroglycerin (NTG) monotherapy. This phenomenon may arise from unopposed neurohormonal vasoconstriction because of rapid elimination of NTG. The role of NTG pharmacokinetics in the development of hemodynamic rebound was examined using a rat model of congestive heart failure. NTG was infused for 90 min, then the dose was either abruptly stopped (n = 8) or gradually reduced by 20% every 20 min (n = 7). Abrupt withdrawal caused rebound elevations of left ventricular end-diastolic pressure (LVEDP) to about 25% above baseline values, at 30-60 min after drug termination (P < 0.01), but this was completely avoided by graded NTG withdrawal. A positive correlation was observed (P < 0.05) between the percentage reduction in LVEDP during infusion and the maximum percentage rebound in rats after abrupt withdrawal but not after graded withdrawal. These results suggest that NTG-induced hemodynamic rebound is related to its short biological half-life and that this phenomenon is consistent with a mechanism of neurohormonal compensation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234174     DOI: 10.1023/a:1018930032203

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine.

Authors:  J Dupuis; G Lalonde; R Lemieux; J L Rouleau
Journal:  J Am Coll Cardiol       Date:  1990-10       Impact factor: 24.094

2.  Withdrawal symptoms in workers exposed to nitroglycerine.

Authors:  R P Lund; J Häggendal; G Johnsson
Journal:  Br J Ind Med       Date:  1968-04

3.  Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.

Authors:  P W Armstrong; J A Armstrong; G S Marks
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

4.  Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.

Authors:  M Packer; J Meller; N Medina; M Yushak; R Gorlin
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

5.  Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.

Authors:  U Elkayam; D Kulick; N McIntosh; A Roth; W Hsueh; S H Rahimtoola
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

6.  Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule.

Authors:  M Ferratini; S Pirelli; P Merlini; P Silva; G Pollavini
Journal:  Eur Heart J       Date:  1989-11       Impact factor: 29.983

7.  Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure.

Authors:  J A Bauer; H L Fung
Journal:  Circulation       Date:  1991-07       Impact factor: 29.690

8.  Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure.

Authors:  M T Olivari; P F Carlyle; T B Levine; J N Cohn
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

9.  Pharmacokinetics of nitroglycerin in rats.

Authors:  P S Yap; H L Fung
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

10.  Regional vascular adjustments during recovery from myocardial infarction in rats.

Authors:  H Drexler; E J Toggart; M R Glick; J Heald; S F Flaim; R Zelis
Journal:  J Am Coll Cardiol       Date:  1986-07       Impact factor: 24.094

View more
  6 in total

1.  Relationship between pharmacokinetics and hemodynamic effects of inhaled isobutyl nitrite in conscious rats.

Authors:  W Kielbasa; H L Fung
Journal:  AAPS PharmSci       Date:  2000

2.  Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

Authors:  Christine Ahlström; Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-04       Impact factor: 2.745

3.  Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris.

Authors:  S Y Martsevich; N Koutishenko; V I Metelitsa
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

Review 4.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

5.  Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure.

Authors:  J A Bauer; H L Fung
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

Review 6.  Mechanisms of nitrate tolerance.

Authors:  H L Fung; J A Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.